These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

249 related articles for article (PubMed ID: 19075682)

  • 21. Technological Evolution in the Development of Therapeutic Antibodies.
    Fajardo-Ramírez ÓR; Ascacio-Martínez JA; Licea-Navarro AF; Villela-Martínez LM; Barrera-Saldaña HA
    Rev Invest Clin; 2015; 67(3):158-69. PubMed ID: 26202739
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Clinical Development and Regulatory Pathways of Monoclonal Antibodies in Japan.
    Liao H; Li Z
    Ther Innov Regul Sci; 2022 Mar; 56(2):173-183. PubMed ID: 34825323
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Current trends in the clinical development of peptide therapeutics.
    Saladin PM; Zhang BD; Reichert JM
    IDrugs; 2009 Dec; 12(12):779-84. PubMed ID: 19943221
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Towards the implementation of quality by design to the production of therapeutic monoclonal antibodies with desired glycosylation patterns.
    del Val IJ; Kontoravdi C; Nagy JM
    Biotechnol Prog; 2010; 26(6):1505-27. PubMed ID: 20665659
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Antibodies to watch in 2010.
    Reichert JM
    MAbs; 2010; 2(1):84-100. PubMed ID: 20065640
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Next-generation monoclonals less profitable than trailblazers?
    Mitchell P
    Nat Biotechnol; 2005 Aug; 23(8):906. PubMed ID: 16082347
    [No Abstract]   [Full Text] [Related]  

  • 27. Harnessing Fc receptor biology in the design of therapeutic antibodies.
    Sondermann P; Szymkowski DE
    Curr Opin Immunol; 2016 Jun; 40():78-87. PubMed ID: 27038127
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Changes in regulations for approval of therapeutics.
    Reichert JM
    MAbs; 2010; 2(4):359-60. PubMed ID: 25225706
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Anti-GD2 mAbs and next-generation mAb-based agents for cancer therapy.
    Perez Horta Z; Goldberg JL; Sondel PM
    Immunotherapy; 2016 Sep; 8(9):1097-117. PubMed ID: 27485082
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Optimism after much pessimism: what next?
    Milstein C; Waldmann H
    Curr Opin Immunol; 1999 Oct; 11(5):589-91. PubMed ID: 10508713
    [No Abstract]   [Full Text] [Related]  

  • 31. Therapeutic breakthroughs in the millennium: what to look for in the next two decades. Part 2: New therapeutics reverse old thinking.
    Davidson S
    Health Forum J; 1999; 42(2):61-3. PubMed ID: 10538905
    [No Abstract]   [Full Text] [Related]  

  • 32. Monoclonal antibodies as anti-infective products: a promising future?
    Pelfrene E; Mura M; Cavaleiro Sanches A; Cavaleri M
    Clin Microbiol Infect; 2019 Jan; 25(1):60-64. PubMed ID: 29715552
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Therapeutic monoclonal antibodies and the need for targeted pharmacovigilance in India.
    Kalaivani M; Singh A; Kalaiselvan V
    MAbs; 2015; 7(1):276-80. PubMed ID: 25523367
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Development trends for monoclonal antibody cancer therapeutics.
    Reichert JM; Valge-Archer VE
    Nat Rev Drug Discov; 2007 May; 6(5):349-56. PubMed ID: 17431406
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Development trends for therapeutic antibody fragments.
    Nelson AL; Reichert JM
    Nat Biotechnol; 2009 Apr; 27(4):331-7. PubMed ID: 19352366
    [No Abstract]   [Full Text] [Related]  

  • 36. Marketed therapeutic antibodies compendium.
    Reichert JM
    MAbs; 2012; 4(3):413-5. PubMed ID: 22531442
    [TBL] [Abstract][Full Text] [Related]  

  • 37. The future of antibodies as cancer drugs.
    Reichert JM; Dhimolea E
    Drug Discov Today; 2012 Sep; 17(17-18):954-63. PubMed ID: 22561895
    [TBL] [Abstract][Full Text] [Related]  

  • 38. The use of monoclonal antibodies for the treatment of epithelial ovarian cancer (review).
    Oei AL; Sweep FC; Thomas CM; Boerman OC; Massuger LF
    Int J Oncol; 2008 Jun; 32(6):1145-57. PubMed ID: 18497976
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Research and development of next generation of antibody-based therapeutics.
    Li J; Zhu Z
    Acta Pharmacol Sin; 2010 Sep; 31(9):1198-207. PubMed ID: 20694021
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Research and development of therapeutic mAbs: An analysis based on pipeline projects.
    Geng X; Kong X; Hu H; Chen J; Yang F; Liang H; Chen X; Hu Y
    Hum Vaccin Immunother; 2015; 11(12):2769-76. PubMed ID: 26211701
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 13.